Mereo Biopharma Group PLC

Mereo BioPharma Group plc announced that all resolutions proposed at its 2026 Annual General Meeting of Shareholders were passed, including the adoption of annual accounts and the re-appointment of auditors and directors.

Mereo BioPharma reports Q1 2026 financial results, highlighting progress in setrusumab's regulatory engagement for pediatric OI and ongoing partnership discussions for alvelestat.

Mereo BioPharma announced Q1 2026 financial results, highlighting progress in regulatory discussions for setrusumab in pediatric OI and active partnership talks for alvelestat.

Dr. Annalisa Jenkins will not seek re-election to Mereo BioPharma Group PLC's Board of Directors at the upcoming 2026 annual general meeting.

Mereo BioPharma announced its full year 2025 financial results, highlighting setrusumab's failure to meet primary endpoints in Phase 3 OI studies despite positive secondary outcomes, and an extended cash runway into mid-2027.

Mereo BioPharma announced an updated cash runway to mid-2027 and reported that its setrusumab Phase 3 studies in osteogenesis imperfecta did not meet primary endpoints for fracture reduction.

Mereo BioPharma reports a narrower net loss for Q1 2026 compared to the prior year, driven by lower administrative expenses and foreign currency gains, alongside increased R&D spending primarily on setrusumab.

Mereo BioPharma Group PLC reported a reduced net loss for Q3 2025, driven by non-operating gains, but saw a significant decrease in cash and reiterated the need for future funding.

Mereo BioPharma reported an increased net loss in Q2 2025, driven by higher R&D for setrusumab, while securing a new milestone payment and extending its cash runway into 2027.

Mereo BioPharma Group reports a net loss of $12.9 million for Q1 2025, while advancing its rare disease therapeutic pipeline.

Mereo BioPharma's Q3 2024 report shows a net loss of $15 million, but the company's cash position is strong following a recent capital raise.

Mereo BioPharma reports its financial results for the second quarter of 2024, highlighting a recent capital raise and clinical progress with its lead drug candidate.

Mereo BioPharma Group PLC reported its 2025 annual results, revealing Setrusumab's Phase 3 trials for Osteogenesis Imperfecta failed primary fracture reduction endpoints, alongside continued operating losses and a Nasdaq minimum bid price non-compliance notice.

Mereo BioPharma Group PLC files its 10-K for the year ended December 31, 2024, detailing its financial results and progress in developing innovative therapeutics for rare diseases, particularly setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency.

Mereo BioPharma Group plc provides a description of its ordinary shares and American Depositary Shares (ADSs) registered under the Securities Exchange Act of 1934.

Mereo BioPharma Group plc Director Pierre Jacquet received equity awards, including share options and deferred restricted stock units, as part of his compensation.

Mereo BioPharma Group plc director Marc J Yoskowitz received 66,000 share options and 96,163 deferred restricted stock units.

Mereo BioPharma Group plc Director Daniel Shames acquired 66,000 share options and 96,163 deferred restricted stock units, increasing his beneficial ownership.

Mereo BioPharma Group plc Director Anders Ekblom was granted 66,000 share options and 133,560 deferred restricted stock units.

Mereo BioPharma Group plc Director Jeremy Bender was granted 66,000 share options and 117,533 deferred restricted stock units on February 26, 2026.

Mereo BioPharma Group plc Director Deepika Pakianathan was granted 66,000 share options with an exercise price of $0.39, vesting over one year.

Mereo BioPharma Group plc has issued its proxy statement for the 2026 Annual General Meeting, detailing proposals for shareholder votes including the adoption of annual accounts, auditor re-appointment, and director re-elections.

Mereo BioPharma Group plc will hold its Annual General Meeting on May 13, 2025, to vote on key resolutions including the adoption of the annual report, auditor re-appointment, director re-elections, and executive compensation.

Mereo BioPharma Group plc will hold its Annual General Meeting on May 23, 2024, to vote on key resolutions including the adoption of the annual report, auditor re-appointment, and director re-elections.

Investment firm EcoR1 Capital and Oleg Nodelman have reported an 8.4% beneficial ownership stake in Mereo BioPharma Group plc.

Bank of America Corporation has reported a beneficial ownership of 5.1% in Mereo BioPharma Group plc, holding 40,976,460 ordinary shares.

Janus Henderson Group plc filed an amended Schedule 13G, reporting a 0.0% beneficial ownership in Mereo Biopharma Group PLC as of December 31, 2025.

Frazier Life Sciences and its affiliated entities have reported a 0.0% beneficial ownership in Mereo BioPharma Group plc, indicating a full divestment of their previous stake.

EcoR1 Capital, LLC and its affiliates have reported a 9.4% beneficial ownership stake in Mereo BioPharma Group plc, held passively as of January 2, 2026.

683 Capital Management, LLC and its affiliates have reported a passive beneficial ownership of 8.18% in Mereo BioPharma Group plc.